Federal contract award
75N93019C00057
TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $15.1M |
| Current contract value | $15.1M |
| Potential contract value / ceiling | $28.9M |
| Start date | Sep 9, 2019 |
| Current end date | Aug 11, 2024 |
| Potential end date | Aug 17, 2024 |
| Latest award activity | Aug 20, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 18 of 18 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 20, 2026 | P00017 | $-57.3K | TO ADMINISTRATIVELY DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Sep 23, 2025 | P00016 | $-38.5K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Jul 31, 2024 | P00015 | $750.0K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Jun 10, 2024 | P00014 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Mar 26, 2024 | P00013 | $473.2K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Jan 31, 2024 | P00012 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Dec 5, 2023 | P00011 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Sep 25, 2023 | P00010 | $489.4K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Sep 12, 2023 | P00009 | $3.8M | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Feb 22, 2023 | P00008 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Nov 18, 2022 | P00007 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Apr 29, 2022 | P00006 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Dec 18, 2021 | P00005 | $271.6K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Jun 24, 2021 | P00004 | $611.8K | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Mar 3, 2021 | P00003 | $0 | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Feb 19, 2021 | P00002 | $3.6M | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Mar 4, 2020 | P00001 | $1.8M | PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G. |
| Aug 30, 2019 | 0 | $3.4M | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.